Molina Healthcare stock (US60855R1005): Ambitious 2029 EPS targets unveiled at Investor Day

Molina Healthcare has laid out aggressive long?term financial targets, including $25 of adjusted EPS by 2029, at its 2026 Investor Day, signaling a turnaround plan after a recent earnings setback.

Molina Healthcare has laid out ambitious long?term financial targets, including a goal of $25 of adjusted earnings per share by 2029, at its 2026 Investor Day on May 8, 2026, signaling a turnaround plan after a recent earnings setback. The company also reiterated at least $5 of adjusted EPS for 2026, with pretax margins expected to expand from below 1% in 2026 to about 2.5% by 2029, according to Morningstar as of 05/08/2026.

At the same event, Molina detailed how it plans to drive margin expansion through medical?cost discipline, operational efficiencies, and continued growth in its Medicaid and Medicare businesses. The company reported a significant adjusted loss per share of $2.75 on $10.7 billion of premium revenue in the latest period, largely due to unexpected retroactive premium adjustments, according to Smartkarma as of 05/08/2026. Despite the near?term headwinds, management emphasized that the 2029 targets are underpinned by a clear path to improved profitability.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Molina Healthcare, Inc.
• Sector/industry: Managed healthcare / health insurance
• Headquarters/country: Long Beach, California, United States
• Core markets: Medicaid, Medicare, and state insurance marketplaces in the United States
• Key revenue drivers: Premium revenue from government?sponsored health plans and related services
• Home exchange/listing venue: New York Stock Exchange (ticker: MOH)
• Trading currency: USD

Molina Healthcare: core business model

Molina Healthcare provides managed healthcare services primarily to low?income families and individuals under the Medicaid and Medicare programs, as well as through state insurance marketplaces in the United States. The company contracts with federal and state governments to administer health plans, earning premium revenue in exchange for managing medical costs and care delivery for enrollees, according to Molina Healthcare as of 05/08/2026.

This government?sponsored model exposes Molina to policy and regulatory shifts, including changes in federal funding formulas, state budget decisions, and program eligibility rules. At the same time, the company benefits from relatively stable, long?term contracts and a large, recurring customer base tied to public?health programs, which can support predictable cash flows once medical?cost trends are under control.

For US retail investors, Molina offers exposure to the managed?care segment of the healthcare sector, which is closely tied to federal and state healthcare spending. The company’s performance is therefore sensitive to macro drivers such as inflation in medical costs, interest?rate?sensitive investment income, and political debates over Medicaid and Medicare funding.

Main revenue and product drivers for Molina Healthcare

Molina’s main revenue driver is premium revenue from its Medicaid and Medicare Advantage plans, which together account for the bulk of its business. In the latest reporting period, the company generated about $10.7 billion of premium revenue, though results were weighed down by an adjusted loss per share of $2.75 due to retroactive premium adjustments, according to Smartkarma as of 05/08/2026.

Within Medicaid, Molina focuses on serving low?income populations in multiple states, often through managed?care organizations that coordinate primary, specialty, and hospital care. In Medicare Advantage, the company targets seniors who enroll in private plans that replace traditional Medicare, offering additional benefits and care?management tools. Growth in both segments is driven by enrollment trends, contract renewals, and the ability to manage medical?cost ratios effectively.

At its Investor Day, Molina highlighted that pretax margin expansion from below 1% in 2026 to about 2.5% by 2029 is central to its long?term plan. This implies tighter control over medical?cost trends, higher operating leverage, and disciplined capital allocation, all of which are critical for delivering the targeted $25 of adjusted EPS by 2029, according to Morningstar as of 05/08/2026.

Why Molina Healthcare matters for US investors

Molina Healthcare matters for US investors because it offers a leveraged play on the managed?care segment of the healthcare sector, which is deeply embedded in federal and state healthcare programs. The company’s fortunes are closely tied to Medicaid and Medicare spending, making it a barometer for policy and budget decisions in Washington and state capitals.

For income?oriented investors, Molina’s potential to improve margins and earnings over the next several years could support future dividend growth or share?repurchase activity, although the company has not emphasized dividends in recent communications. For growth?oriented investors, the 2029 EPS target of $25 represents a multi?year narrative of margin expansion and earnings recovery, assuming management can execute on its cost?control and operational plans.

At the same time, US investors should be aware that Molina’s business is highly regulated and sensitive to political risk. Changes in federal funding formulas, state budget pressures, or shifts in Medicaid and Medicare policy could materially affect premiums, enrollment, and profitability, adding volatility to the stock.

Conclusion

Molina Healthcare has set an ambitious long?term target of $25 of adjusted EPS by 2029, up from at least $5 in 2026, as part of a broader turnaround plan after a recent earnings setback. The company’s strategy hinges on expanding pretax margins from below 1% in 2026 to about 2.5% by 2029 through medical?cost discipline and operational improvements, according to Morningstar as of 05/08/2026.

For US investors, Molina offers exposure to the managed?care segment of the healthcare sector, with a business model closely tied to Medicaid and Medicare programs. The stock’s performance will depend on how well management navigates medical?cost trends, regulatory changes, and political risk, while delivering on its long?term financial targets.

This article does not constitute investment advice. Stocks are volatile financial instruments, and investors should consider their own risk tolerance and investment horizon before making any decisions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.